Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
about
Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthmaAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenAddition to inhaled corticosteroids of long-acting beta 2-agonists versus anti-leukotrienes for chronic asthmaAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenRegular treatment with salmeterol for chronic asthma: serious adverse eventsLong-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adultsAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenAddition of anti-leukotriene agents to inhaled corticosteroids for chronic asthmaAdd-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive reviewDoes zafirlukast reduce future risk of asthma exacerbations in adults? Systematic review and meta-analysisAntileukotriene agents for the treatment of lung diseaseEffect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trialsTreating children with asthma. A review of drug therapies.Leukotriene receptor antagonist therapyAntileukotrienes in asthma: present situation.Long-acting inhaled beta(2)-agonist therapy in asthma.Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma.Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management.Inhaled corticosteroids plus long-acting beta2-agonists as a combined therapy in asthma.Novel therapies for the treatment of inflammatory airway disease.Combination therapy: appropriate for everyone?Leukotriene receptor antagonists--risks and benefits for use in paediatric asthma.A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmaticsAdd-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotypeFluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma.Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.Beta2-agonist eutomers: a rational option for the treatment of asthma?Designing a series of decision-theoretic phase II trials in a small population.Use and safety of long-acting β2-agonists for pediatric asthma
P2860
Q24197585-43B81E16-FF73-4E40-BA7F-FFDDBADABD39Q24197682-15B644A7-C9BF-4A9E-A494-F0795E7BB33AQ24200999-588AF16E-B8F1-4097-ABFD-2DB88CF954C6Q24234499-D7C872E8-FCBB-48D4-A1EC-C692B4E0F533Q24235303-277EBA4E-DB54-44E8-B8D2-51D610375CB9Q24235964-C7CF48C9-A2A5-444A-931A-BE4D1C1F301AQ24240464-C53E9D60-9C86-4D26-AB9E-FECC0B77238AQ24241960-E88F21F5-FBC9-4B86-B8E4-469E13FEC707Q24244152-74AAB673-4467-4948-A284-DA9C77CA088CQ24245719-F856880B-168A-4D3E-BD04-BCDF73D6B200Q24247433-0DEED9C9-D09B-4C98-A683-3F67D09FD9D1Q24247489-3B73B2F3-7015-46BE-A816-45A012239CCFQ24794527-EA0DE949-A961-4805-B10E-81B25144ED8BQ26863510-3BD34979-7609-4761-8D6E-FC076CD9D232Q28293842-3B98C251-A3FE-407A-A0B1-023E52E61671Q28344299-F0FB53FB-4BBB-433E-B702-CE2C9ABCF8CBQ33729027-A182C8B6-AECE-4D79-849D-34B0BFB36F6DQ34086351-5D098517-B32C-4D7B-85D3-F7F6E6F0F9C9Q34240893-DB48EAAB-CF07-4C46-826E-FD2D58F21C57Q34392656-7E982DAF-0103-439B-B221-EFE16DE2C7BAQ34424227-9318FB65-11DD-4364-A5B1-C661E4886FD5Q34523871-6C8321B8-193B-446E-A027-BE9C8AB29EECQ35040750-9B47782C-E7F6-4EE6-9975-BF5B88303830Q35040779-6B7157D4-E000-4F51-8744-7AEFCC71C602Q35180953-8748976E-0D9F-47F0-AC94-28FE9E0749C1Q35779312-28C6EB57-6DB3-483A-BC74-4592FC2AC57AQ35825361-CC46BA7E-D7D9-4743-961C-0D3FCB6FF205Q35825639-FD6A0356-D73B-4712-A2A6-01CA3AFA473CQ36506711-5CEF13C1-8738-4CAE-AB54-71873A3406C8Q39724263-F5E07371-2D04-4F95-B5E6-134356E48573Q44726379-C7946715-9514-4B4E-989F-6695D051D609Q47215345-1A712788-EFDB-44C4-B024-92427A4D1733Q57821604-6140B83B-34AA-4A21-8EAD-90471D986B5F
P2860
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@ast
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@en
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@nl
type
label
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@ast
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@en
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@nl
prefLabel
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@ast
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@en
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@nl
P2093
P1476
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
@en
P2093
P304
P356
10.1016/S0091-6749(99)70182-X
P407
P577
1999-06-01T00:00:00Z